News

In order to avoid a public health crisis and keep up with increasing vision loss among the aging baby-boomer generation, correctable vision impairments must be eliminated by 2030, according to a report issued by the National Academies of Sciences, Engineering, and Medicine (NASEM).

An increasing number of treatment options have given patients facing diabetic macular edema (DME) new hope in the face of this chronic, progressive, and blinding disease. Experience and time have shown us there is not a one-size-fits-all solution for patients with DME. To get the results we want, we need to screen our patients and match them with the treatment protocol best suited to their needs.

Ready for some big news? Johnson & Johnson announced they have entered into a definitive agreement to acquire Abbott Medical Optics (AMO) for $4.325 billion in cash. AMO’s business segments include cataract surgery, laser refractive surgery, and consumer eye health, and reported sales in 2015 were $1.1 billion.

When it comes to their eyes, patients want the safest treatments, and they know the best technology available is a laser. The cataract patient demographic is changing, and patients today have active lifestyles that demand functional vision.

Achieving spectacle independence for distance vision after toric IOL implantation depends on the refractive outcome. Factors affecting residual astigmatism and studies evaluating the use of various surgical techniques and technologies relating to those factors are discussed.

When Martin Luther King said, “I have a dream,” he had a vision for people, not a program. Visionary leaders have the ability to communicate values and ideas in a way that connects. In your practice, they bring certainty into the uncertain world of reimbursement rates and rapid change. What is your capacity to bring vision and direction into times of uncertainty?

Aflibercept remains superior to bevacizumab after 2 years of treating patients with poor baseline visual acuity (VA) caused by diabetic macular edema (DME), but it loses its edge over ranibizumab, researchers said.

Watch as Regis Kowalski, Executive Director, The Charles T. Campbell Laboratory at the University of Pittsburgh, explains how newly discovered resurgent isolates may affect clinical practice.